Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

Loibl, S. ; Azim, H. A. ; Bachelot, T. ; Berveiller, P. ; Bosch, A. LU ; Cardonick, E. ; Denkert, C. ; Halaska, M. J. ; Hoeltzenbein, M. and Johansson, A. L.V. , et al. (2023) In Annals of Oncology 34(10). p.849-866
Abstract

The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer (BC) treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be... (More)

The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer (BC) treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline. The aim of this consensus-building process was to discuss controversial issues relating to the management of patients with PrBC. The virtual meeting included a multidisciplinary panel of 24 leading experts from 13 countries and was chaired by S. Loibl and F. Amant. All experts were allocated to one of four different working groups. Each working group covered a specific subject area with two chairs appointed: 1. PrBC: incidence, epidemiology, biology and pathology, diagnostic work-up, staging and risk assessment, prognosis (Chairs: Vincent Vandecaveye, Fedro Peccatori). 2. Clinical pharmacology of systemic agents during pregnancy: management of localized disease and (neo) adjuvant therapies, management of systemic disease (Chairs: Giuseppe Curigliano, Peter Schmid). 3. Obstetric care and fetal/newborn follow-up and outcomes: metastases to fetus, management of pregnancy during anticancer therapy, lactation, psychological support (Chairs: Elyce Cardonick, Mathilde van Gerwen). Planning, preparation and execution of the consensus process was conducted according to the ESMO standard operating procedures.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
(neo) adjuvant therapy, pregnancy management during cancer, pregnancy-related breast cancer
in
Annals of Oncology
volume
34
issue
10
pages
18 pages
publisher
Oxford University Press
external identifiers
  • pmid:37572987
  • scopus:85170414993
ISSN
0923-7534
DOI
10.1016/j.annonc.2023.08.001
language
English
LU publication?
yes
id
37c13d00-8dfb-49b1-b0fe-44d0bc1af714
date added to LUP
2024-01-12 15:23:53
date last changed
2024-04-27 10:44:44
@article{37c13d00-8dfb-49b1-b0fe-44d0bc1af714,
  abstract     = {{<p>The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer (BC) treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline. The aim of this consensus-building process was to discuss controversial issues relating to the management of patients with PrBC. The virtual meeting included a multidisciplinary panel of 24 leading experts from 13 countries and was chaired by S. Loibl and F. Amant. All experts were allocated to one of four different working groups. Each working group covered a specific subject area with two chairs appointed: 1. PrBC: incidence, epidemiology, biology and pathology, diagnostic work-up, staging and risk assessment, prognosis (Chairs: Vincent Vandecaveye, Fedro Peccatori). 2. Clinical pharmacology of systemic agents during pregnancy: management of localized disease and (neo) adjuvant therapies, management of systemic disease (Chairs: Giuseppe Curigliano, Peter Schmid). 3. Obstetric care and fetal/newborn follow-up and outcomes: metastases to fetus, management of pregnancy during anticancer therapy, lactation, psychological support (Chairs: Elyce Cardonick, Mathilde van Gerwen). Planning, preparation and execution of the consensus process was conducted according to the ESMO standard operating procedures.</p>}},
  author       = {{Loibl, S. and Azim, H. A. and Bachelot, T. and Berveiller, P. and Bosch, A. and Cardonick, E. and Denkert, C. and Halaska, M. J. and Hoeltzenbein, M. and Johansson, A. L.V. and Maggen, C. and Markert, U. R. and Peccatori, F. and Poortmans, P. and Saloustros, E. and Saura, C. and Schmid, P. and Stamatakis, E. and van den Heuvel-Eibrink, M. and van Gerwen, M. and Vandecaveye, V. and Pentheroudakis, G. and Curigliano, G. and Amant, F.}},
  issn         = {{0923-7534}},
  keywords     = {{(neo) adjuvant therapy; pregnancy management during cancer; pregnancy-related breast cancer}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{849--866}},
  publisher    = {{Oxford University Press}},
  series       = {{Annals of Oncology}},
  title        = {{ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)}},
  url          = {{http://dx.doi.org/10.1016/j.annonc.2023.08.001}},
  doi          = {{10.1016/j.annonc.2023.08.001}},
  volume       = {{34}},
  year         = {{2023}},
}